Puretech Health Plc Stock Today

PRTC Stock  USD 19.08  1.77  10.23%   

Performance

Soft

 
Weak
 
Strong

Odds Of Distress

Low

 
High
 
Low
PureTech Health is trading at 19.08 as of the 23rd of January 2026, a 10.23 percent increase since the beginning of the trading day. The stock's open price was 17.31. PureTech Health has less than a 18 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. The performance scores are derived for the period starting the 25th of October 2025 and ending today, the 23rd of January 2026. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
16th of November 2020
Category
Healthcare
Classification
Health Care
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company has 24.17 M outstanding shares of which 5.02 K shares are at this time shorted by private and institutional investors with about 4.27 trading days to cover. More on PureTech Health PLC

Moving against PureTech Stock

  0.65TVTX Travere TherapeuticsPairCorr
  0.6CNTA Centessa PharmaceuticalsPairCorr
  0.52GALT Galectin TherapeuticsPairCorr
  0.5TARA Protara TherapeuticsPairCorr
  0.36OBIO Orchestra BioMed HoldingsPairCorr
  0.34RARE UltragenyxPairCorr

PureTech Stock Highlights

ESG Sustainability
Environmental
Governance
Social
CoFounder PresidentEric Elenko
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Debt Levels
PureTech Health can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand PureTech Health's financial leverage. It provides some insight into what part of PureTech Health's total assets is financed by creditors.
Liquidity
PureTech Health PLC currently holds 22.36 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. PureTech Health PLC has a current ratio of 2.49, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about PureTech Health's use of debt, we should always consider it together with its cash and equity.

Change In Cash

84.63 Million
PureTech Health PLC (PRTC) is traded on NASDAQ Exchange in USA and employs 56 people. PureTech Health is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 461.01 M. PureTech Health PLC conducts business under Biotechnology sector and is part of Health Care industry. The entity has 24.17 M outstanding shares of which 5.02 K shares are at this time shorted by private and institutional investors with about 4.27 trading days to cover. PureTech Health PLC currently holds about 368.03 M in cash with (134.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.84.
Check PureTech Health Probability Of Bankruptcy
Ownership Allocation
PureTech Health owns a total of 24.17 Million outstanding shares. Roughly 99.58 pct. of PureTech Health outstanding shares are held by general public with 0.42 (%) by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check PureTech Ownership Details

PureTech Stock Institutional Holders

InstituionRecorded OnShares
Birch Hill Investment Advisors Llc2025-06-30
242.7 K
Pentwater Capital Management Lp2025-06-30
50 K
Portolan Capital Management, Llc2025-06-30
27.8 K
Millennium Management Llc2025-06-30
23.9 K
Diadema Partners Lp2025-06-30
7.3 K
Persistent Asset Partners Limited2025-06-30
1.7 K
Atlantic Union Bankshares Corp2025-06-30
115
Ubs Group Ag2025-06-30
20.0
Morgan Stanley - Brokerage Accounts2025-06-30
0.0
View PureTech Health Diagnostics

PureTech Health Historical Income Statement

At present, PureTech Health's Gross Profit is projected to decrease significantly based on the last few years of reporting. The current year's EBIT is expected to grow to about 40.8 M, whereas Depreciation And Amortization is forecasted to decline to about 3.9 M. View More Fundamentals

PureTech Stock Against Markets

PureTech Health Corporate Management

Frank SalisburySenior StrategyProfile
Michael ChenChief SeaportProfile
Anita JDSenior PropertyProfile
Lauren MBAChief OfficerProfile
RDN MSChief OfficerProfile
David ElmalehCoFounder AdvisorProfile
When determining whether PureTech Health PLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of PureTech Health's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Puretech Health Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Puretech Health Plc Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PureTech Health PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PureTech Health. If investors know PureTech will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PureTech Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.615
Earnings Share
1.7
Revenue Per Share
0.27
Quarterly Revenue Growth
5.427
Return On Assets
(0.13)
The market value of PureTech Health PLC is measured differently than its book value, which is the value of PureTech that is recorded on the company's balance sheet. Investors also form their own opinion of PureTech Health's value that differs from its market value or its book value, called intrinsic value, which is PureTech Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PureTech Health's market value can be influenced by many factors that don't directly affect PureTech Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PureTech Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if PureTech Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PureTech Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.